Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer - implications for dosing schedule and neoadjuvant study consideration

Author： Hall M.C.   Fritzsch R.J.   Sagalowsky A.I.   Ahrens A.   Petty B.   Roehrborn C.G.  

Publisher： Elsevier

ISSN： 0090-4295

Source： Urology, Vol.53, Iss.5, 1999-05, pp. : 898-902

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer

By Kobayashi Takashi   Nishizawa Koji   Mitsumori Kenji  

Scandinavian Journal of Urology and Nephrology, Vol. 40, Iss. 3, 2006-05 ,pp. : 198-203

Informa Healthcare

Access to resources Recommend Favorite

Menstruation recovery after chemotherapy and luteinizing hormone-releasing hormone agonist plus tamoxifen therapy for premenopausal patients with breast cancer

By Sakurai Kenichi   Matsuo Sadanori   Enomoto Katsuhisa   Amano Sadao   Shiono Motomi  

Surgery Today, Vol. 41, Iss. 1, 2011-01 ,pp. : 48-53

Springer Publishing Company

Access to resources Recommend Favorite

Squamous cell carcinoma of the prostate: a transformation from adenocarcinoma after the use of a luteinizing hormone-releasing hormone agonist and flutamide

By Braslis K.G.   David R.C.   Nelson E.   Civantos F.   Soloway M.S.  

Urology, Vol. 45, Iss. 2, 1995-02 ,pp. : 329-331

Elsevier

Access to resources Recommend Favorite

Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment

By Oefelein M.G.  

Urology, Vol. 54, Iss. 4, 1999-10 ,pp. : 694-699

Elsevier

Access to resources Recommend Favorite

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer

By Schellhammer P.   Sharifi R.   Block N.   Soloway M.   Venner P.   Patterson A.L.   Sarosdy M.   Vogelzang N.   Jones J.   Kolvenbag G.  

Urology, Vol. 45, Iss. 5, 1995-05 ,pp. : 745-752

Elsevier

Access to resources Recommend Favorite